Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Colorcon
Merck
AstraZeneca
Federal Trade Commission
Mallinckrodt
Healthtrust
Express Scripts
UBS

Generated: June 18, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CUTIVATE

« Back to Dashboard

Clinical Trials for CUTIVATE

Trial ID Title Status Sponsor Phase Summary
NCT00119158 Combination Therapy for Atopic Dermatitis Completed Novartis Pharmaceuticals Phase 4 Atopic dermatitis is a chronic relapsing disease with acute flares. The standard therapy is to treat acute flares using topical medications. The two most common classes of topical medications for atopic dermatitis (AD) are topical corticosteroids and topical calcineurin inhibitors. Pimecrolimus and topical corticosteroids exert their activity by different mechanisms, there may be a synergistic effect of the combination therapy. Therefore, a combination therapy may provide a faster resolution of severe skin lesions and consequently reduce the duration of the topical corticosteroid treatment. Another benefit of the combination therapy maybe the use of a lower potency corticosteroid to achieve the same degree of clearance. The hypothesis of this trial is that the combination of the two agents will lead to faster clearance than the single agent of topical corticosteroids.
NCT00119158 Combination Therapy for Atopic Dermatitis Completed Children's Hospital of Philadelphia Phase 4 Atopic dermatitis is a chronic relapsing disease with acute flares. The standard therapy is to treat acute flares using topical medications. The two most common classes of topical medications for atopic dermatitis (AD) are topical corticosteroids and topical calcineurin inhibitors. Pimecrolimus and topical corticosteroids exert their activity by different mechanisms, there may be a synergistic effect of the combination therapy. Therefore, a combination therapy may provide a faster resolution of severe skin lesions and consequently reduce the duration of the topical corticosteroid treatment. Another benefit of the combination therapy maybe the use of a lower potency corticosteroid to achieve the same degree of clearance. The hypothesis of this trial is that the combination of the two agents will lead to faster clearance than the single agent of topical corticosteroids.
NCT00546000 Cutivate Lotion HPA Axis Pediatric Study Completed Fougera Pharmaceuticals Inc. Phase 4 A multi-center, open-label, Phase IV, unblinded study using Cutivate (fluticasone propionate, 0.05%)lotion and it's possible effects on the HPA axis of infants diagnosed with atopic dermatitis.
NCT00763529 Elocon vs Fluticasone in Localized Psoriasis (P03197)(COMPLETED) Completed Schering-Plough Phase 4 This is an open-label, randomized, parallel-group clinical study. The primary objective is to assess the difference in response rate between mometasone furoate cream 0.1% (once daily) vs fluticasone propionate cream 0.05% (twice daily) by the end of Day 4 and Day 8 in the management of Indian patients with localized psoriasis.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Clinical Trial Conditions for CUTIVATE

Condition Name

Condition Name for CUTIVATE
Intervention Trials
Atopic Dermatitis 2
Psoriasis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for CUTIVATE
Intervention Trials
Dermatitis 2
Eczema 2
Dermatitis, Atopic 2
Psoriasis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for CUTIVATE

Trials by Country

Trials by Country for CUTIVATE
Location Trials
United States 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for CUTIVATE
Location Trials
Texas 2
Illinois 1
Colorado 1
Pennsylvania 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for CUTIVATE

Clinical Trial Phase

Clinical Trial Phase for CUTIVATE
Clinical Trial Phase Trials
Phase 4 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for CUTIVATE
Clinical Trial Phase Trials
Completed 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for CUTIVATE

Sponsor Name

Sponsor Name for CUTIVATE
Sponsor Trials
Novartis Pharmaceuticals 1
Schering-Plough 1
Fougera Pharmaceuticals Inc. 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for CUTIVATE
Sponsor Trials
Industry 3
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
McKinsey
Johnson and Johnson
Queensland Health
Deloitte
US Department of Justice
McKesson
Julphar
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.